Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
Equillium, Inc. (Nasdaq: EQ) announced that its CEO, Bruce Steel, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The presentation will provide a high-level overview of itolizumab’s mechanism of action followed by topline data from the company’s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD), regulatory feedback leading directly to a pivotal study in aGVHD, and the EQUALISE study in systemic lupus erythematosus and lupus nephritis. Members of Equillium’s leadership team will be available for one-on-one meetings during the conference.
A webcast of the presentation will be available under the “Investors” section of the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx for 90 days.
About
For more information, visit www.equilliumbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005418/en/
Investor Contact
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com
Media Contacts
Aljanae Reynolds
areynolds@wheelhouselsa.com
Source: